image credit- shutterstock
Docquity, the Singapore-based clinical AI platform for more than 75% of verified doctors across Asia, has announced its scale up plan into Japan through a deepened strategic partnership with exMedio Inc., operator of the specialist physician communities Hematology Pro and Hipokura.
The move advances Docquity's goal of building Asian Healthcare Intelligence, grounded in Clinical Intent: what doctors across Asia need answered at the point of care.
Docquity Holdings and Docquity Japan G.K. have signed a Memorandum of Understanding (MoU) with exMedio that places Ask Dx, Docquity's clinical AI assistant, at the core of the partnership.
The MoU builds on a collaboration that began in 2025, when Docquity first offered Ask Dx to members of Hipokura, exMedio's clinical consultation community of more than 80,000 physicians. The relationship now moves from supplying an AI tool to building clinical support for Japanese physicians together, and to connecting physician communities in Japan and Southeast Asia.
The partnership pairs exMedio's specialist network and understanding of Japanese clinical practice with Docquity's clinical AI and its physician network across Asia. It will concentrate on knowledge sharing and clinical support in oncology, and services will be developed with feedback from physicians in Japan.
Under the MoU, Docquity and exMedio will explore exchange and knowledge sharing between physician communities in Japan and Southeast Asia.
